Neurology Today in 5

In this week’s podcast, Neurology Today’s editor-in-chief discusses data on an angiotensin receptor for blocker for hypertension associated with reduced risk for epilepsy, a study finding first responders to 9-11 clean-up sites had an increased risk for early dementia, and dementia experts comment on approval of donanemab.

In this week’s podcast, Neurology Today’s editor-in-chief discusses data on the effectiveness of rescue therapies when endovascular thrombectomy fails, how first-seizure clinics reduce hospitalizations, and AI’s use in sleep neurology.

In this week’s podcast, Neurology Today’s editor-in-chief discusses a paper advising against prematurely withdrawing life support for severe TBI, data showing those with the highest composite score of inflammatory markers had a greater risk for stroke, original reporting stressing that residency programs and applicants need to adopt more strategic approaches to managing the ov

In this week’s podcast, Neurology Today’s editor-in-chief discusses a push among neurocritical care experts to develop a code procedure for intracerebral hemorrhage, new findings showing people with Havana syndrome have functional neurologic disorder, and a study reporting distal symmetric polyneuropathy is more prevalent but less diagnosed in primary care clinics in low-incom

In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting better outcomes with surgical removal of hematoma in intracerebral hemorrhage, disparities in access to diagnosis and care for epilepsy, and the challenges that remain for women in neurology research.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.